High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Adult patients (greater than 18 years)
* Primary resection
* Histologically confirmed retroperitoneal, abdominal or pelvic soft tissue sarcoma
* R0/R1 resection
* Eligible whether or not the participant undergoes neoadjuvant treatment

Exclusion Criteria:

* Metastatic disease at time of randomisation
* Recurrent, metastatic or residual disease identified on baseline CT imaging (3-4 months post primary resection)
* Reoperation for recurrent soft tissue sarcoma
* Re-resection following previous inadequate surgery
* R2 resection
* Patients receiving adjuvant therapy that will delay, interrupt or render radiological surveillance unpredictable
* Uterine sarcomas, gastrointestinal stromal tumour (GIST), fibromatosis, epithelial tumours, multifocal disease, sarcomas of bony origin
* Patient declined to consent to data sharing with RESAR (unless in a centre contributing via pre-planned IPDMA)